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Motivational, proteostatic
and transcriptional deficits
precede synapse loss, gliosis
and neurodegeneration in the
B6.HttQ111/+ model of Huntington’s
disease
Robert M. Bragg1, Sydney R. Coffey1, Rory M. Weston1,2, Seth A. Ament3,4, Jeffrey P. Cantle1,
Shawn Minnig1, Cory C. Funk3, Dominic D. Shuttleworth1, Emily L. Woods1,
Bonnie R. Sullivan1, Lindsey Jones1, Anne Glickenhaus1, John S. Anderson1,
Michael D. Anderson1, Stephen B. Dunnett5, Vanessa C. Wheeler6, Marcy E. MacDonald6,
Simon P. Brooks5, Nathan D. Price3 & Jeffrey B. Carroll1,6
We investigated the appearance and progression of disease-relevant signs in the B6.HttQ111/+ mouse,
a genetically precise model of the mutation that causes Huntington’s disease (HD). We find that
B6.HttQ111/+ mice are healthy, show no overt signs of central or peripheral inflammation, and no gross
motor impairment as late as 12 months of age. Behaviorally, we find that 4–9 month old B6.HttQ111/+
mice have normal activity levels and show no clear signs of anxiety or depression, but do show clear
signs of reduced motivation. The neuronal density, neuronal size, synaptic density and number of glia is
normal in B6.HttQ111/+ striatum, the most vulnerable brain region in HD, up to 12 months of age. Despite
this preservation of the synaptic and cellular composition of the striatum, we observe clear progressive,
striatal-specific transcriptional dysregulation and accumulation of neuronal intranuclear inclusions
(NIIs). Simulation studies suggest these molecular endpoints are sufficiently robust for future preclinical
studies, and that B6.HttQ111/+ mice are a useful tool for modeling disease-modifying or neuroprotective
strategies for disease processes before the onset of overt phenotypes.
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by expansion
of a glutamine-coding CAG trinucleotide repeat near the 5’ end of the HTT gene1. The identification of the
disease-causing mutation did not point to an obvious set of therapeutic approaches, given that the huntingtin protein is a very large HEAT/HEAT-like repeat solenoid scaffold2, which is highly evolutionarily conserved, and vital
to normal development3. A key effort in preclinical HD research is understanding the link between polyglutamine
expansion in huntingtin and the selective cellular toxicity in corticostriatal circuits which is thought to cause disease symptoms. A range of animal models of the HD mutation have been developed to investigate this question,
including knock-in and transgenic mice as well as transgenic rats, sheep, pigs and nonhuman primates4. Unique
amongst described models, knock-in mice with varying allele sizes provide the ability to quantitatively study the
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Age

Sex

Genotype

Measured
n CAG (SD)

3 Months

M

B6.Htt+/+

9

3 Months

M

B6.Htt Q111/+

9

3 Months

F

B6.Htt+/+

9

3 Months

F

B6.Htt Q111/+

9

9 Months

M

B6.Htt+/+

9

9 Months

M

B6.Htt Q111/+

9

9 Months

F

B6.Htt+/+

9

9 Months

F

B6.Htt Q111/+

9

12 Months

M

B6.Htt+/+

9

12 Months

M

B6.Htt Q111/+

9

12 Months

F

B6.Htt+/+

9

12 Months

F

B6.HttQ111/+

9

Terminal Body
Weight (SD)
24.3 (1.7)

113 (3.3)

23.8 (1.4)
18.2 (0.7)

114 (2.5)

17.2 (1.4)
28.2 (1.8)

113 (5.0)

31.4 (1.8)
23.3 (1.2)

113 (3.3)

23.5 (1.6)
30.6 (2.6)

N/A

31.4 (1.6)
25.2 (3.7)

N/A

26.1 (2.5)

Table 1. Cohort 2 characteristics.

relationship between CAG size and pathogenesis in an otherwise isogenic system5. Recent molecular6 and behavioral7 analyses of an allelic series of HD knock-in mice reveal very discrete CAG-dependent disease signatures,
suggesting these mice recapitulate a cardinal feature of human HD, namely the relationship between CAG tract
length and the rapidity of disease progression3,8. Because knock-in models express Htt at endogenous levels from
the endogenous locus they precisely mimic the genetics of human HD, however their use in preclinical studies has
been limited because their overt neurological signs are very subtle compared to transgenic animals9,10. The bulk
of preclinical research has therefore been conducted in transgenic models expressing either full-length or short
fragments of mutant huntingtin, which display more phenotypes11.
The embracing of transgenic models by the field has largely been driven by the desire to model important signs
and symptoms of HD, including progressive striatal atrophy and hyperkinetic motor disturbances. We consider
that these phenomena emerge from a substrate of decades of progressive cellular and physiological dysfunction
before manifesting in human patients as a set of clinical signs recognizable as “Huntington’s disease”12. Targeting
these late features of the disease process, including cell death and emergent motor symptoms, may enable the
modification of late HD symptoms. However, this strategy doesn’t allow targeting of the earliest disease changes
that precede overt clinical disease features, which if clearly identified might ultimately provide paths to prevention and/or early-stage reversal. Finally, no HD mouse model develops chorea-like hyperkinetic movements, and
mouse models present with modest striatal volume loss over the lifespan of the mouse13,14, while human disease
results in the nearly complete atrophy of this critical structure15.
We and others acknowledge that knock-in mouse models of HD cannot fully recapitulate clinical symptoms
that, in human mutation carriers, require approximately four decades of pathogenic processes to emerge and are
followed by a further 15 years to progress to death16. However, these genetically faithful but subtle mouse models
provide us the ability to study the earliest and subtlest changes caused by the CAG expansion of Htt - the very
processes we wish to understand if we are to develop interventions to prevent the development of clinical HD
onset, rather than addressing its symptoms only after significant damage to key processes has been incurred.
Towards this end, we have here characterized the earliest observable changes in the murine B6.HttQ111/+ (hereafter HttQ111/+) model of the HD mutation17. Since their creation, these mice have been utilized to test specific
hypotheses in a wide range of studies18, and a single unbiased phenotypic screen10, but have not been well characterized as a system for conducting preclinical studies. We therefore examined the incidence, progression and
statistical power of a range of phenotypes in these mice, and find that they provide a powerful tool for studying
hypotheses about the early disease events that stem from the HD CAG expansion mutation. We observe robust
transcriptional, proteostatic and motivational phenotypes which progress from 3 to 12 months of age in HttQ111/+
mice. Simulation studies suggest interventions that rescue specific signs by 10–25% are readily detectable in
appropriately powered preclinical studies, making the HttQ111/+ mouse a useful tool for testing disease modifying
therapeutics in HD.

Results

General Animal Health and Inflammation. Consistent with previous reports of HttQ111/+ mice on the
CD1 and B6J strains9,10, no body weight changes were observed between 3 and 12 months of age (effect of genotype, F(1,94) = 3.1, p = 0.07, mean CAG length = 113, cohort summary in Table 1). Important plasma chemistry
parameters, including protein, glucose and ion concentrations, as well as liver enzyme levels, were normal at 4
months of age in HttQ111/+ mice10. Because we are interested in progressive phenotypes, we examined a suite of
clinical chemistry parameters at 12 months of age - no changes were observed in any of these parameters in male
HttQ111/+ mice at this age (Table 2). Consistent with findings in younger mice, and coupled with body weight
observations, these results suggest that up to 12 months of age HttQ111/+ mice are grossly healthy. Subtle increases
in concentrations of pro-inflammatory chemokines and cytokines have been observed in presymptomatic HD
mutation carriers19 and some (e.g. YAC128), but not all (e.g. BACHD), transgenic HD mice by 12 months of
age20. To understand whether increased peripherally-detectable inflammation is occurring in HttQ111/+ mice we
quantified cytokines, chemokines and acute phase reactants in the plasma of 12-month-old, male HttQ111/+ mice
Scientific Reports | 7:41570 | DOI: 10.1038/srep41570

2

www.nature.com/scientificreports/
Analyte

Units

+/+(SD)

Q111/+ (SD)

EGF

pg/mL

201 (31.7)

211 (24.6)

T-test
0.64

Eotaxin

pg/mL

2170 (1044)

1368 (173)

0.18

IL-1 beta

ng/mL

8.975 (2.1)

9.45 (1.3)

0.71

IL-18

ng/mL

20.8 (4)

25.3 (1.5)

0.08

IP-10

pg/mL

60 (42.2)

64.5 (19.8)

0.85

LIF

pg/mL

915.3 (173.6)

722.8 (129.3)

0.13
0.49

MCP-1

pg/mL

55.5 (28.9)

43 (17.6)

MCP-3

pg/mL

293.5 (195.4)

204.8 (30.2)

0.4

MCP-5

pg/mL

17.7 (7.5)

16.5 (3.3)

0.78

M-CSF-1

ng/mL

3.45 (1.1)

4.3 (0.2)

0.19

MDC

pg/mL

2157.5 (1099.5)

1470 (216.9)

0.27

MIP-1 alpha

ng/mL

5.4 (0.8)

5.4 (0.5)

1

MIP-3 beta

ng/mL

3.3 (0.6)

2.5 (0.2)

0.05

Thrombopoietin

ng/mL

35 (7.7)

37.5 (5.2)

0.61

TIMP-1

ng/mL

1.4 (1)

1.15 (0.1)

0.65

VEGF-A

pg/mL

185.5 (28.4)

192.5 (27.8)

0.74

Glucose

mg/dl

253.3 (20.6)

238.2 (85.4)

0.74

BUN

mgld

22.8 (4.2)

23 (4.5)

0.93

Creatine

mg/ld

0.05 (0.05)

0.02 (0)

0.4

Phosphate

mg/dl

6.45 (0.1)

7.68 (1.1)

0.06

Total Protein

g/dl

3.5 (0.1)

3.4 (0.2)

0.48

Albumin

g/dl

2 (0.01)

1.94 (0.1)

0.41

Globulin

g/dl

1.5 (0.05)

1.46 (0.1)

0.82

Albumin/Globulin

Ratio

1.4 (0.06)

1.34 (0.2)

0.91

Total Bilirubin

mg/dl

0.1 (0)

0.18 (0.2)

0.41

U/L

0.75 (0.5)

0.8 (0.4)

0.88
0.65

ALP
GGT

U/L

1 (0.8)

1.2 (0.4)

ALT

U/L

33 (11.4)

40.4 (24.4)

0.6

AST

U/L

60 (17.6)

78.6 (32.4)

0.34

mg/dl

54.5 (11.2)

56.2 (15)

0.86

Cholesterol

Table 2. Clinical chemistry parameters are normal in 12 month old HttQ111/+ mice. Top level analytes are
from inflammationMAP (Myriad RBM, Austin, TX, USA), lower level analytes are from clinical chemistry
panel (Phoenix Central Labs, Mukilteo, WA, USA). Abbreviations: epidermal growth factor (EFG), interleukin
(IL), interferon gamma-induced protein (IP), monocyte chemoattractant protein (MCP), macrophage colonystimulating factor (M-CSF), macrophage-derived chemokine (MDC), macrophage inflammatory proteins
(MIP), tissue inhibitor of metalloproteinase (TIMP), vascular endothelial growth factor-A (VEGF-A),
alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate
aminotransferase (ASP). Inflammation markers measured below LLoQ (LLoQ listed): Fibroblast growth factor
(FGF)−9 (2.4 ng/mL), FGF-basic (9.6 ng/mL), granulocyte-macrophage colony-stimulating factor (15 pg/mL),
keratinocyte chemoattractant/human growth-regulated oncogene (0.028 ng/mL), interferon gamma (182 pg/mL),
IL-1 alpha (100 pg/mL), IL-2 (70 pg/mL), IL-3 (5.9 pg/mL), IL-4 (60 pg/mL), IL-5 (0.6 ng/mL), IL-6 (4.7 pg/mL),
IL-7 (0.19 ng/mL), IL-10 (125 pg/mL), IL-11 (56 pg/mL), IL-12p70 (0.091 ng/mL), IL-17A (0.018 ng/mL), MIP-1
beta (142 pg/mL), MIP-2 (11 pg/mL), oncostatin-M (0.24 ng/mL), stem cell factor (652 pg/mL), tumor necrosis
factor-alpha (0.082 ng/mL). N = 4 male HttQ111/+, 4 male Htt+/+, subset of 12-month mice from Table 1).

(multi-analyte profiling, Myriad RBM). We successfully quantified 16 of these molecules (Table 2: Eotaxin, EGF,
IP-10, IL-1β, IL-18, LIF, M-CSF-1, MDC, MIP-1α, MIP-3β, MCP-1, MCP-3, MCP-5, Thrombopoietin, TIMP-1,
VEGF-A) but observed no changes in 12-month-old HttQ111/+ mice. Other important pro-inflammatory molecules (FGF9, FGF-basic, GM-CSF, KC/GRO, IFN-γ, IL-1α, IL-2, −3, −5, −6, −7, −10, −11, −12p70, −17a,
MIP1-β, OSM, SCF, and TNF-α) were also assayed, but fell below the indicated limit of detection in all mice
studied (lower limit of quantification, LLoQ, provided in Table 2). These data suggest that peripherally-detectable
immune activation is either not occurring in 12-month-old, male HttQ111/+ mice, or is sufficiently subtle to be
missed by these analyses.

Striatal Transcriptional Alterations. Altered transcription is an early and prominent feature of HD
pathology, and is observed in both animal models and samples from human patients12. Because we are interested in intervening at the earliest possible point in the pathogenic process, we investigated the time course of
transcriptional changes in the central nervous system of HttQ111/+ mice. As an initial, untargeted pilot study,

Scientific Reports | 7:41570 | DOI: 10.1038/srep41570

3

www.nature.com/scientificreports/

Figure 1. Progressive, striatal-specific, transcriptional dysregulation in the aging HttQ111/+ brain. (a) The
impact of genotype on the expression level of each of the 19,031 transcripts assayed is indicated - statistical
significance on the y-axis (-log10 FDR), and fold-change on the x-axis (log fold-change, HttQ111/+/Htt+/+). Color
indicates statistical significance - black indicates FDR > 0.1, red and blue indicate FDR < 0.1 for up- and downregulated genes in the HttQ111/+ striatum, respectively. (b) Network diagram depicting the 8 reactome pathways
with adjusted p-values less than 0.05 in a hypergeometric analysis, and the proportion of genes shared between
each pathway. The size of each node corresponds to the overall gene set size (e.g. signaling by GPCR pathway
includes 853 genes, Gαz signalling events 44), while the width of the edges corresponds to the Jaccard similarity
coefficient for the pair of gene sets (the intersection of the two sets divided by its union). (c) Network diagram
depicting the 15 reactome pathways whose genes are non-randomly distributed on the ordered list of striatal
transcripts with an FDR < 0.1, and the proportion of genes shared between each pathway. Blue nodes indicate
down-regulated pathways, while red nodes indicate upregulation in the 9 month old HttQ111/+ striatum.

we examined striatal and cerebellar genome-wide transcriptional changes in 3- and 9-month-old HttQ111/+ mice
using mRNA sequencing (RNASeq). At 3 months of age, no robust transcriptional alterations were detected in
the striatum of HttQ111/+ mice compared to wild-type mice (Fig. 1a, 5 quantified transcripts - Lct, Zfp385c, Smpx,
Dsp, Crlf1 - have an effect of genotype with a false discovery rate (FDR) of < 5%). By 9 months of age, 726 transcripts were changed in the striatum of HttQ111/+ mice compared to wild-type mice (Fig. 1a, 245 up-regulated, 481
down-regulated at FDR < 5%). The cerebellum, despite robustly expressing mutant Htt21–23, is relatively spared
from pathological tissue loss in human HD patients24 and the YAC128 mouse model of HD14. We therefore compared the rate and scale of transcriptional dysregulation between the cerebellum and striatum of HttQ111/+ mice
at 3 and 9 months of age. There were very few significant effects of CAG expansion in Htt in the cerebellum at
either age (Fig. 1a, 3 genotype-sensitive transcripts, 2 down-regulated, 1 up-regulated at FDR < 5%). These data
confirm that, as in humans with HD and other animal models, progressive striatal transcriptional dysregulation
is a feature of aging HttQ111/+ mice.
We next examined pathway enrichment of dysregulated transcripts using both hypergeometric25 and gene set
enrichment analysis (GSEA)26 techniques. The hypergeometric test examines over-enrichment of differentially
expressed genes in a specific pathway, while GSEA quantifies whether a set of pathway genes is over-represented
at the top or bottom of an ordered list of genes - here, the full list of 9-month striatal transcripts, ordered by the
fold-change in HttQ111/+ mice compared to wild-type mice. Hypergeometric testing of 726 genotype-sensitive
(FDR < 5%) striatal transcripts (from a gene universe of 19,031 robustly assayed genes) revealed significant
enrichment of striatal genotype-sensitive transcripts in 8 pathways with an adjusted p-value < 0.05, notably in
neuronal signaling pathways (Fig. 1b). GSEA revealed 15 gene sets significantly enriched (FDR < 0.1) at the high
or low end of the list of striatal transcripts, ordered by their genotype expression ratio (HttQ111/+/Htt+/+; Fig. 1c).
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Nineteen common pathways had nominal enrichment p-values < 0.05 in both GSEA and hypergeometric analyses, including Reactome pathways involved in neurotransmission and cellular signaling (e.g. transmission across
chemical synapses, neuronal system, signaling by GPCR, and GPCR downstream signaling; Table S1), suggesting
synaptic and signaling transcripts are altered at the transcriptional level in the 9-month-old HttQ111/+ striatum.
To orthogonally validate the observed striatal transcriptional alterations and examine their relevance
as useful preclinical tools in HttQ111/+, we quantified specific transcript levels in the striatum of 3-, 9- and 12month-old HttQ111/+ mice using quantitative real-time polymerase chain reaction (QRT-PCR). As predicted
by cross-sectional RNASeq data (Fig. 1), transcript levels of the critical striatal signaling gene Ppp1r1b, that
encodes the protein dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP32) are normal in
HttQ111/+ mice at 3 months of age, but reduced at both 9 and 12 months of age (effect of genotype F(1,47) = 6.74,
p = 0.01, Figure 2a). Similarly, we find that levels of a suite of additional neuronal signaling and synaptic genes
(including: Cnr1, Drd2, Homer1, Pde10a, Penk, Scn4b) are reduced in aged (9- and 12-month-old) but not young
(3-month-old) HttQ111/+ mice (Fig. 2a, effect sizes for each target shown in Fig. 2b). Other transcripts increase
over time in HttQ111/+ and include genes involved in DNA damage (e.g. N4bp2) or immune response (e.g. Islr2,
H60b, Fig. 2a). These results confirm the findings of our RNAseq study and suggest that levels of a range of transcripts are sensitive genotype markers in the aging HttQ111/+ striatum.

Striatal Histology.

We also considered a range of histological endpoints in the dorsolateral striatum of 3-,
9- and 12-month-old HttQ111/+ mice. Compared to tissue-level analyses such as RNASeq and QRT-PCR, immunohistochemistry (IHC) enables the identification of specific cell types and analysis of subcellular localization.
First, a trivial explanation for the observed transcriptional alterations in the striatum of the HttQ111/+ mice is
that the cellular composition or relative cell sizes within the striatum has changed. To examine this possibility,
we counted putative neurons, astrocytes and microglia in the dorsolateral striatum (respectively: NeuN-, glial
fibrillary acidic protein- and allograft inflammatory factor 1-immunoreactive cells). Between 3–12 months of
age, the neuronal density in the dorsolateral striatum of HttQ111/+ mice does not change (Fig. 3a, F(1, 100) = 0.03,
p = 0.87), nor does the cross-sectional area of NeuN-immunoreactive soma in the dorsolateral striatum at 9
months (NeuN-immunoreactive cell size distributions shown in Fig. 3b, two-sample Kolmogorov-Smirnov (K-S)
test D = 0.02, p = 0.9). We next quantified astrocytic and microglial density in the dorsolateral striatum of 12
month old HttQ111/+ and Htt+/+ mice, finding that neither is increased in 12 month old HttQ111/+ mice (Fig. 3d).
Progressive loss of synaptophysin density has been reported in transgenic HD and other neurodegenerative disease mouse models27. We quantified synaptophysin density in the dorsolateral striatum and find that HttQ111/+
and Htt+/+ mice have equivalent levels of synaptophysin staining from 3–12 months of age (Fig. 3c, F(1, 93) = 3.71,
p = 0.057). These results suggest that the robust transcriptional alterations we observe in the aging HttQ111/+ striatum (Fig. 1) are not due to altered numbers or size of neurons, loss of synaptic compartments and that overt
gliosis is not a component of the phase of HD modeled by the HttQ111/+ mice.
We also examined the appearance of aggregated striatal huntingtin using the MW8 antibody, which detects
aggregated, but not diffuse, mutant huntingtin28, but to our knowledge has not yet been applied to study
HttQ111/+ mice. We restricted our analyses to neuronal cell bodies, immunoreactive for NeuN, a well-described
pan-neuronal marker29. In the dorsolateral striatum of 3-month-old HttQ111/+ mice there is virtually no neuronal
MW8 immunoreactivity, but by 9 months of age we observe robust accumulation of both small punctate and
large inclusion staining in neuronal nuclei (Fig. 4a). Between 9 and 12 months of age, increased levels of neuronal intranuclear inclusions (NII) in the HttQ111/+ striatum are accompanied by a reduction in the total nuclear
MW8 immunoreactivity. Total neuronal nuclear MW8 immunoreactivity increases from 3 to 9 months of age,
before declining at 12-months of age (Kruskal-Wallis: H(5) = 80.7, p < 0.0001, Dunn: 3-month genotype p = 0.15,
9-month genotype p < 0.0001, 12-month genotype p < 0.0001; Fig. 4b). This rise and fall in total neuronal nuclear
MW8 immunoreactivity is accompanied by a progressive increase in the percentage of cells with large NIIs,
from 0% at 3-months to 13% at 9-months and 28% by 12 months of age (Kruskal-Wallis: H(5) = 87.9, p < 0.0001,
Dunn: 3-month genotype p = 1, 9-month genotype p < 0.0001, 12-month genotype p < 0.0001, Fig. 4c). In parallel, the average size of striatal NIIs in HttQ111/+ mice increases more than 40% from 1.3 ± 0.7 μm at 9 months
to 1.8 ± 0.9 μm at 12 months of age (two-sample K-S test, D = 0.29, p < 0.0001). Impaired autophagy has been
proposed to contribute to impaired proteostasis in HD29,30, and in the brain mHTT interacts directly with p62/
Sqstm1, an autophagic receptor protein important for selective macroautophagy31. We observed complete
co-localization between p62 and MW8 immunoreactivity in striatal NII’s in HttQ111/+ mice (Fig. 4d) suggesting
that, as has been observed in cell culture31, p62 is found in NIIs. We finally considered whether quantitative
IHC for specific MSN targets is superior to QRT-PCR quantification. As a proof of concept, we quantified neuronal DARPP32 levels in corticostriatal sections. Consistent with mRNA reductions (Fig. 2), we observe reduced
neuronal somatic DARPP32 levels in the HttQ111/+ striatum (Fig. 5; Kruskal-Wallis: H(5) = 19.6, p = 0.0015,
Dunn: 3-month genotype p = 0.12, 9-month genotype p = 0.09, 12-month genotype p = 0.006). We find that,
for DARPP32, quantification of IHC data is more variable than QRT-PCR when establishing reductions in the
HttQ111/+ striatum.

Behavioral Analyses. We cross-sectionally analyzed behavior in several cohorts of 3–9 month old HttQ111/+

mice, including assays of motivation, anhedonia, depression, and anxiety (cohorts described in methods). We
first measured reward seeking behavior in HttQ111/+ mice using an operant fixed ratio 1 (FR1) behavioral assay to
examine how many sweet rewards mice will perform for in a 5 minute block at 6 months of age. We found that
HttQ111/+ mice demonstrate reduced reward attainment relative to Htt+/+ mice (Fig. 6a; Genotype: F(1,14) = 17.0,
p = 0.001: Genotype x Reward Size: F(2,28) = 8.4, p = 0.001). In an attempt to discern hedonic from motivational
explanations for this reduced reward attainment, we examined preference for either 2% or 4% sucrose in drinking
water in a separate cohort of mice. We found no difference between 9 month old Htt+/+ and HttQ111/+ mice (2%
Scientific Reports | 7:41570 | DOI: 10.1038/srep41570
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Figure 2. Confirmation of progressive transcriptional dysregulation in the striatum of aging HttQ111/+
mice using quantitative real-time polymerase chain reaction. (a) Guided by transcriptional discovery
with RNAseq, we quantified a number of transcripts and found that many synaptic and neuronal signalling
transcripts were down as mice aged from 3-months to 9- and 12- months. As anticipated, we also found
upregulated transcripts related to immune and DNA damage pathways (N = 60, subset of 5 mice per row
from Table 1). Data are presented as boxplots. (b) Corresponding longitudinal effect sizes for each transcript
(highlighted in colored bands above) are displayed in the same color below, with whiskers representing the
95% confidence interval range. Along the x-axis, transcripts are ordered by increasing effect size at 12-months,
though robust effects are seen at both 9- and 12-months. Our results demonstrate that these transcripts are
sensitive genotype markers that make suitable targets for assessing rescue in interventional trials using the
HttQ111/+ mouse model.
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Figure 3. No evidence of changes in striatal cell distribution, neuronal cell size or a synaptic marker in
HttQ111/+ mice through 12 months of age. (a) NeuN+ cell density is not changed between HttQ111/+ and Htt+/+
mice at 3, 9, or 12 months of age (three image frames analyzed per mouse). ANOVA: Genotype F(1, 100) = 0.03,
p = 0.87, Age F(2, 100) = 98.9, p < 0.0001, Interaction F(2, 100) = 2.79, p = 0.07. Data presented as boxplots. (b)
Distribution of striatal NeuN+ cell sizes does not differ between HttQ111/+ and Htt+/+ striata at 9 months of age.
Two-sample K-S test D = 0.02, p = 0.98, N = 2038 cells, one image frame analyzed per mouse. (c) Synaptophysin
staining intensity was examined at 3, 9, and 12 months of age, showing no differences between HttQ111/+ and
Htt+/+ mice (one image frame analyzed per mouse). ANOVA: Genotype F(1, 93) = 3.7, p = 0.057, Age
F(2, 93) = 16.7, p < 0.0001, Interaction F(2, 93) = 1.5, p = 0.22. Data presented as boxplots. (d) Glia counts at 12
months show no difference in numbers of GFAP+ astrocytes (green; t(32) = 1.2, p = 0.25.) and Aif1+ microglia
(red; t(31) = 0.2, p = 0.9) in HttQ111/+ versus Htt+/+ striata. Representative Htt+/+ section shown. Data presented
as boxplots.

sucrose Genotype x Sucrose concentration: F(1,38) = 0.03, p = 0.87; 4% sucrose Genotype x Sucrose concentration:
F(1,35) = 0.41, p = 0.53, Figure S1). However, we did find HttQ111/+ mice demonstrate a stronger preference for
sucrose pellets (Genotype: F(1,14) = 15.9, p = 0.001, Fig. 6b). Taken together, these tests demonstrate no inherent
lack of sucrose preference in HttQ111/+ mice that is present in Htt+/+ mice.
To explore the potential contributions of anxiety or depression to the observed reward attainment changes we
conducted several tests of these phenotypes in a separate cohort of 9-month old Htt+/+ and HttQ111/+ mice. First
we conducted the Porsolt swim test, a measure of behavioral despair30, where we observe no differences between
9-month old Htt+/+ and HttQ111/+ mice in the duration of time spent inactive during the task (Fig. 6c; t(38) = 0.8,
p = 0.9). Similarly, using the elevated plus maze task as a measure of anxiety32, we found that 9-month-old Htt+/+
and HttQ111/ mice do not differ in the amount of time spent in the open arms (Fig. 6d; t(37) = 0.7, p = 0.5), or in
the percentage of total arm entries into the open arms, (t(37) = −1.3, p = 0.2). As a final measure of anxiety levels
in HttQ111/+ mice, we also employed the light/dark exploration task 32,33, finding that Htt+/+ and HttQ111/+ mice
spend the same amount of time in the light and dark halves of the apparatus (Fig. 6e; t(38) = 0.04, p = 0.9) and
enter the light compartment of the maze a similar number of times (t(38) = −0.6, p = 0.5). Altogether, these data
suggest that up to 9-months of age HttQ111/+ mice do not display anxiety-related or depressive-like symptoms, and
declines observed in reward seeking behavior may reflect presently undefined cognitive or motivational issues
worthy of additional study.

Power Analysis for preclinical studies in HttQ111/+ mice. To establish the utility of the natural history
data collected here (QRT-PCR and IHC), we conducted several power analysis studies to understand whether
these results would be useful in a preclinical trial setting. We considered a hypothetical 2 × 2 factorial experiment,
with two genotypes (Htt+/+vs. HttQ111/+) and two treatment groups (baseline vs. a hypothetical treatment). We
simulated data for Htt+/ and HttQ111/+ mice in the ‘treatment’ condition by drawing values from a random normal distribution with the same mean, variance, and covariance as our real natural history data. Assuming a 50%
rescue from a hypothetical intervention, we established the power of single molecular endpoints in a preclinical
Scientific Reports | 7:41570 | DOI: 10.1038/srep41570
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Figure 4. Progressive accumulation of p62 - and huntingtin-immunoreactive neuronal intranuclear
inclusions (NIIs) in the striatum of aging HttQ111/+ mice. (a) Images of the dorsolateral striatum taken in
5-μm sections of 12-month mice triple labelled for neurons (Red; NeuN), nuclei (Blue; DAPI) and aggregated
huntingtin (Green; MW8). Accumulation of both large neuronal-nuclear HTT aggregates, as well as small
huntingtin nuclear speckles is present in HttQ111/+, but absent in Htt+/+ mice. (b) Total neuronal nuclear MW8
immunoreactivity increases from 3 to 9 months of age, before declining at 12 months of age (Kruskal-Wallis:
H(5) = 80.7, p < 0.0001, Dunn: 3-month genotype p = 0.15, 9-month genotype p < 0.0001, 12-month genotype
p < 0.0001; N = 108, breakdown in Table 1. (c) Using a neuronal (NeuN) mask with particle inclusion from
0.5–5 μm2 shows a median of 10% of neurons contain large nuclear aggregates by 9-months, which increases
to 27% at 12 months of age. The presence of NIIs provides a robust measure for huntingtin accumulation with
an extremely robust effect size for genotype comparisons at 9- and 12-months (d = 1.6 and 6.7, respectively;
error bars = 95% confidence interval). Kruskal-Wallis: H(5) = 87.9, p < 0.0001, Dunn: 3-month genotype p = 1,
9-month genotype p < 0.0001, 12-month genotype p < 0.0001; N = 108, breakdown Table 1. (d) Images colabelled for aggregated huntingtin (Green; MW8), and autophagy adaptor protein p62 (Red), demonstrate p62
is colocalized with aggregated huntingtin in 12-month HttQ111/+ mice.

study with 10 animals per arm (4 arms - Htt+/+ and HttQ111/+ mice in a treatment or control arm). By 12 months of
age, several individual endpoints provide reasonable power to detect this 50% rescue, including reductions in striatal Scn4b mRNA levels and an increase in MW8-immunoreactive aggregate counts (Fig. 7a). We next considered
whether combining information from multiple molecular endpoints would improve the power to detect a partial
rescue. We trained an elastic net logistic regression model to classify HttQ111/+ versus Htt+/+ mice using a weighted
combination of the QRT-PCR (Scn4b, Drd1a, Cnr1, Darpp32, Homer1) and IHC (mHTT aggregates, mHTT area,
DARPP32, cell counts, neuronal ratio) endpoints in the striatum. This model distinguished HttQ111/+ vs. Htt+/+
mice with > 90% accuracy in training data from 9- and 12-month-old mice. The model assigns non-zero weights
to 0 endpoints in 3-month-old mice, 9 in 9-month-old mice, and 9 in 12-month-old mice (regression coefficients
for individual endpoints provided in Fig. 7d). With a sample size of 10, this multivariate model would have
80% power to detect a 35% rescue in 12-month-old mice or a 60% rescue in 9-month-old mice (Fig. 7b). With
n = 20, the model had 80% power to detect a 25% rescue in 12-month-old mice or a 40% rescue in 9-month-old
mice (Fig. 7c). These results suggest that combining information from multiple molecular endpoints can improve
power to detect subtle effects of treatments.
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Figure 5. Histological analysis confirms protein-level reductions in DARPP32 in the aging HttQ111/+
striatum. (a) DARPP32 staining with NeuN positive cell traces (Yellow) to demonstrate the inclusion areas
for DARPP32 quantification (Top). Representative images of DARPP32, NeuN, and DAPI triple-labelled
dorsolateral striatum highlights interneurons (Red), medium spiny neurons (MSN; Yellow), and nonneuronal cells (Blue). B. DARPP32 immunofluorescence per neuronal cell body is reduced in HttQ111/+ mice
by 12-months (Fig. 5; Kruskal-Wallis: H(5) = 19.6, p = 0.0015, Dunn: 3-month genotype p = 0.12, 9-month
genotype p = 0.09, 12-month genotype p = 0.006, N = 108, breakdown in Table 1). Data are presented as
boxplots, effect size error bars = 95% confidence interval.

Discussion

We have here characterized the health and progression of phenotypes in the HttQ111/+ mouse, which accurately
model the zygosity and Htt expression level of human HD patients. We found that, in contrast to transgenic
N-terminal HTT fragment models of the disease, which have rapidly progressing and terminal disease, the
HttQ111/+ mice were grossly healthy through 12 months of age in terms of body weight, plasma chemistry and both
central and peripheral inflammation, extending previous observations of these mice10. Despite their generally
healthy state in their first year of age, during this interval they presented striatal-specific, progressive, molecular
changes consistent with those observed in other animal models of HD and indeed human mutation carriers, as
well as specific behavioral phenotypes consistent with early HD. Using simulation studies, we demonstrated that
these animals provide a powerful tool for experimental therapeutics targeting these early molecular changes.
In a recent review, Menalled and Brunner11 demonstrated that less than 5% of preclinical studies of reviewed
therapeutic agents in HD were tested in knock-in models of the disease. The R6 and N171 lines of mice, which
transgenically express short fragments of mHtt, were much more commonly used, together comprising 72% of all
preclinical studies examined. Translation from animal models of neurodegeneration to human clinical trials has
been disappointing, with a large number of agents predicted to be useful in transgenic animals failing to provide
clinical benefit in human HD, for example11. A major benefit of screening therapeutics in short fragment mouse
models of HD is that they present robust behavioral phenotypes, including motor alterations, affective impairments and cognitive alterations4. Similar, though less pronounced, phenotypes have been observed in full-length
YAC128 and BACHD mice9. Distinguishing central effects from peripheral ones is difficult in these animals
because they either progressively lose (e.g. R6/234 and N17134,35) or gain (YAC12836 and BACHD9) significant
amounts of body weight in parallel with the development of progressive molecular and behavioral phenotypes.
Large observational studies have suggested that HD patients may, on average, lose weight9,37, as observed in short
fragment mouse models of HD. However, more recently, careful and well-powered studies of presymptomatic HD
mutation carriers and early stage patients reveals they have normal body composition and plasma chemistry38,
consistent with our observations in aging HttQ111/+ mice (Table 1).
While presymptomatic HD mutation carriers do not show clinically obvious motor impairments, by definition, they do show clear sub-clinical cognitive impairments39 and progressive affective alterations. Amongst affective changes in HD mutation carriers, apathy has emerged as the most widely observed40, and uniquely amongst
neuropsychiatric symptoms, progresses in a continuous fashion with disease state40,41. Like presymptomatic HD
mutation carriers, previous studies of HttQ111/+ mice revealed normal gross motor behavior and grip strength
through 12 months of age9,10,42. Recent work with q175 HD knock-in mice suggests they present subtle motivational alterations detected using mixed fixed-/progressive-ratio operant tasks43. Similarly, reduced executive
function has been observed in HttQ111/+ mice using delayed non-match to sample tasks42. The data presented here
(Fig. 6) suggest that 9-month old HttQ111/+ mice do not have enhanced anxiety or depression-like behaviors, but
do show motivational deficits, most notably a reduced performance on a fixed-ratio 1 task, despite normal hedonic
drive for sweet stimuli at this time point. These behavioral studies, in conjunction with the body weight and
Scientific Reports | 7:41570 | DOI: 10.1038/srep41570
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Figure 6. Presence of HttQ111 allele results in reduced reward seeking behavior independent of anxiety-like
or depressive behavior. (a) HttQ111/+ mice display reduced reward attainment compared to Htt+/+ mice across
three reinforcement durations (Rft = 40 ms, 60 ms, & 100 ms with 100 ms being 5 μL) during FR1 operant testing
(Genotype: F(1,14) = 17.0, p = 0.001, Genotype x Reward: F(2,28) = 8.4, p = 0.001). (b) HttQ111/+ mice exhibit a
stronger preference for sucrose pellets during the hours sucrose consumption task compared to Htt+/+ mice
(Genotype: F(1,14) = 15.9, p = 0.001). (c) HttQ111/+ and Htt+/+ mice do not differ in the amount of time spent
inactive during the Porsolt swim task. (d) HttQ111/+ and Htt+/+ mice spend a similar amount of time in the open
arms of the elevated plus maze. (e) HttQ111/+ and Htt+/+ mice do not differ in the amount of time spent in the
light compartment of the apparatus during the light/dark exploration task (a) and (b) are presented as mean
+/- SEM. (c), (d) and (e) are presented as boxplots.

general health data presented here, suggest that HttQ111/+ mice more closely resemble pre-symptomatic mutation
carriers than do short fragment models of HD. Importantly, this suggests interventions targeting apathy, the single
most prevalent and progressive psychiatric manifestation of HD41,40, can be tested in knock-in models of HD.
Transcriptional dysregulation in HD has long been noted in both human samples and samples taken from
experimental models. Here, using mRNA sequencing techniques we provide quantitative evidence about the
degree to which striatal transcriptional changes exceed transcriptional changes in a relatively spared tissue in HD,
the cerebellum. Indeed, at 9 months of age, the striatum has more than 250-fold more differentially expressed
transcripts than does the cerebellum at this age (Fig. 1A). This is consistent with the fact that the cerebellum
is grossly spared from pathological volume change in both human patients24 and full-length mouse models of
HD14. A concern with transcriptional changes in pathologically affected tissue is that tissue architecture changes
(in either cellular composition or relative cell size changes) may explain alterations in mRNA abundance in tissue
level analyses. The evidence presented here suggests that robust transcriptional dysregulation in the striatum of
HttQ111/+ mice precedes any alterations in the density of striatal neurons, astrocytes, microglia or synapses. In fact,
of the presented phenotypes, altered transcript levels are amongst the most powerful features for distinguishing
Htt+/+ from HttQ111/+ mice at 9–12 months of age (Fig. 7). These data confirm that striatal transcriptional dysregulation occurs in the absence of changes in cell number in early HD, occurring the absence of neurodegeneration,
gliosis or overt loss of synapses. Also consistent with previous observations of HttQ111/+ mice at younger ages17, we
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Figure 7. Power analysis suggests multivariate endpoints maximize power for pre-clinical study. (a)
Estimated power to detect a 50% rescue of individual endpoints in 3-, 9- or 12-month-old mice, assuming a
sample size of 10 HttQ111+ mice and 10 Htt+/+ mice in baseline conditions and 10 HttQ111+ mice and 10 Htt+/+
mice given a hypothetical treatment that induces a partial rescue. (b,c) Power to detect partial rescue at each
timepoint using a multivariate elastic net classifier and a sample size of 10 (b) or 20 (c) mice per group. (d)
Regression coefficients (weights) assigned to each biomarker in the elastic net model. Positive and negative
coefficients indicate that the marker is increased or decreased in HttQ111/+ mice, respectively.
Scientific Reports | 7:41570 | DOI: 10.1038/srep41570
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observe progressive striatal-specific accumulation of neuronal intranuclear inclusions (NIIs) in HttQ111/+ mice.
Similar to aggregates found in human HD, these large inclusions are primarily restricted to neurons (we do not
observe any glial NIIs), and co-stain with autophagic cargo marker p62 (Fig. 4). Our power analyses suggest that
treatments that alter either mHTT levels, or improve proteostasis and thereby alter aggregate formation, can be
robustly tested in vivo using the HttQ111/+ mice with adequate power.
While we find that the HttQ111/+ mice provide a number of useful reflections of human HD, there are also
significant limitations to their truly modeling Huntington’s disease. First, even healthy captive mice live only
approximately 2 years44, while human HD generally has onset only after 30–50 years of relatively unaffected
life45. This discrepancy in lifespan may explain why very long CAG repeats (here, approximately 113 - Table 1)
are required to lead to robust molecular or behavioral changes. Repeats of this length would be predicted to cause
juvenile onset HD in the human context, with fulminant behavioral and neuropathological consequences that
are not observed in any mouse models described46. Alternatively, or in addition, the different neural circuity47,
transcriptional and proteomics networks6,48 of the human brain could explain the selective vulnerability of human
neurons to mutant-huntingtin induced cell dysfunction and death.
In summary, we present data suggesting that the HttQ111/+ mice are grossly healthy during their first year of life,
yet present a range of molecular and behavioral alterations consistent with presymptomatic HD mutation carriers. Our power analyses revealed that these changes can provide sufficiently powered endpoints for preclinical
studies of neuroprotective therapies for HD with a reasonable duration and number of subjects. In conjunction
with other recently described cognitive and affective10,42,43 behavioral phenotypes in these animals, we propose
that knock-in models provide greater face validity, and thereby potential translatability, than transgenic models
of HD for future preclinical studies.

Methods
Mice.

We used 4 cohorts (detailed below) of mixed-gender B6.HttQ111/+ mice for the described studies (Research Resource Identifier:IMSR\_JAX:003456). The creation of the HttQ111/+ line has been described5.
Experiments for cohort 1 were conducted in accordance to NIH Guide for the Care and Use of Laboratory
Animals and was approved by the Massachusetts General Hospital (MGH) Subcommittee of Research Animal
Care (SRAC). Experiments for cohort 2 and 3 were conducted in accordance to NIH Guide for the Care and
Use of Laboratory Animals and approved by the Western Washington University (WWU) animal care and use
committee. Experiments for cohort 4 were conducted in accordance to the UK Animals (Scientific) Act 1986,
European Union Directive 2010/63/EU and approved by the Cardiff University local ethical review committee.

Cohort 1 (RNA sequencing). The cohort used to generate the RNASeq data presented in Fig. 1 was gener-

ated at Massachusetts General Hospital (MGH). Cohorts of 58 total mixed-gender littermate mice (12 × 3-month
and 16 × 9-month Htt Q111/+; 12 × 3-month and 16 × 9-month Htt +/+) mice were generated by crossing
B6.HttQ111/+ males with C57Bl/6 J females. The size of the Htt CAG tract ranged from 126 to 135 (mean 131), with
no significant differences observed across the groups of this cohort. The mice were part of a larger study of the
impact of dietary fat on metabolism49 - the mice described in Fig. 1 were fed chow from weaning until 9 months of
age with either 60% kcal/fat (Open Source Diet D12492) or 45% kcal/fat (Open Source Diet D1245). Striatal and
cerebellar transcriptional effects of these diets were collapsed for the analysis presented in Fig. 1.

Cohort 2 (Molecular natural history).

The cohort used to generate the molecular natural history data,
presented in Figs 2–5 and 7, was bred and maintained at the Jackson Labs (Bar Harbor, Maine) and shipped to
the WWU vivarium approximately 2 weeks before the endpoints under investigation. Three groups of mice were
sacrificed at 3 (90 ± 4 days), 9 (295 ± 2 days) or 12 (369 ± 5 days) months of age (Table 1).

Cohort 3 (Behavioral cohort, WWU). The cohort used to collect the behavior data at WWU (Porsolt
swim test, elevated plus maze, light/dark box, sucrose solution preference) were bred and maintained at Jackson
Labs (Bar Harbor, Maine) and consisted 40 female mice (20 Htt+/+; 20 HttQ111/+). Htt CAG tract ranged from 107
to 119 (mean 114). Mice were shipped to the WWU vivarium at 8 months of age and acclimated to reversed light
cycle conditions (lights on from 12 am to 12 pm) for four weeks prior to testing at 9 months of age. Behavioral
assays were conducted between 1:00 pm and 5:00 pm during the active phase.
Cohort 4: (Behavioral cohort, Cardiff). The Cardiff cohort consisted of 16 mice (8 Htt+/+; 8 HttQ111/+),
bred in-house from founders originally obtained from Jackson Labs (Bar Harbor, Maine), was used for the FR1
and sucrose pellet preference experiments. The mice were housed under 12-hour light/dark cycle with free access
to food and water outside of experimental periods. FR1 operant testing began when the mice were 4 months of
age, followed by the sucrose pellet preference experiment at 6 months of age. All experimental procedures were
initiated between 8 am and 9 am.
Tissue isolation and sample processing. After a three hour fast, mice in the molecular natural history cohort
were euthanized via IP sodium pentobarbital injection (Fatal Plus, Henry Schein). Whole blood was collected
by cardiac puncture with EDTA (25 μM) and plasma was extracted. Mice were then transcardially perfused with
phosphate buffered saline (PBS) to clear tissues of blood. Whole brains were extracted and placed in a Brain Slicer
Matrix (Zivic). A midline longitudinal cut was made to separate hemispheres. Coronal cuts were made in the left
hemisphere 1- and 4-mm posterior to the junction between the olfactory bulb and cortex, resulting in a 3-mm
thick corticostriatal block of tissue (Figure S2) that was formalin fixed (6–8 hours), paraffin embedded, sectioned
(5-μm), and mounted onto glass slides for immunohistochemistry. The contralateral hemisphere was dissected
into striatum, cortex, and cerebellum, and flash frozen for molecular analyses.
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Plasma chemistry and immune profiling. Plasma clinical chemistry was measured using an AU2700 Chemistry
Analyzer (Beckman Coulter) at Phoenix Central Laboratories (Mukilteo, WA, USA). A panel of 37 cytokines,
chemokines and acute phase reactants was assessed using a multiplexed cytometric bead array immunoassay
(Mouse InflammationMAP 1.0, Myriad RBM, Inc., Austin, TX, USA).

Library construction, RNA Sequencing and RNASeq analysis. For the RNA Sequencing studies in
Fig. 1, RNA was extracted using the RNeasy Lipid Tissue Mini Kit (Qiagen). Quality control for RNA was conducted using the Agilent 2100 Bioanalyzer with Agilent RNA 6000 Nano kit. Libraries for sequencing were constructed using the Illumina TruSeq RNA Sample Prep Kit and sequenced on a HiSeq 2000 (2 × 50 bp) to a read
depth of 2.4 × 107 ± 6.2 × 106 per sample. The fastq files were aligned using the default parameters of SNAPR50
(https://github.com/PriceLab/snapr) against the GRCh38 genome assembly, along with the transcriptome assembly gtf file from Ensembl, GRCh38.75. SNAPR generates read counts for both genes and transcripts simultaneously with alignment. All alignments were performed on Amazon EC2 c3.8xlarge instance using a Ubuntu14.04
base AMI. Differential gene expression was conducted using the edgeR package51, and pathway enrichment using
HTSanalyzeR52 in Bioconductor53.
mRNA quantification – QRT-PCR. Total RNA was extracted from the right hemi-striatum using the RNeasy
Lipid Tissue Mini Kit (Qiagen). Tissue was homogenized in 500 μL of Qiazol Lysis Reagent for one minute at
4,000 rpm using a homogenizer (BeadBug; Benchmark Scientific). Aqueous and organic phases were separated
by the addition of 100 μL of chloroform. All subsequent steps in were performed according to the manufacturer’s protocol. Reverse transcription was performed using the Superscript III First Strand Synthesis System
(Life Technologies) following the manufacturer’s protocol. Quantitative real-time polymerase chain reaction
(QRT-PCR) was conducted with the resulting cDNA using the Real-Time StepOne System (Applied Biosystems).
Transcripts were analyzed by the relative quantitation standard curve method and normalized to a transcript
unregulated by mutant Htt expression (Actb). All taqman probes were purchased from Life Technologies and
were as follows: Drd1a: Mm02620146\_s1, Drd2: Mm00438545\_m1, Cnr1: Mm01212171\_s1, Darpp32:
Mm00454892\_m1, Penk: Mm01212875\_m1, N4bp2: Mm01208882\_m1, Islr2: Mm00623260\_s1, Pde10a:
Mm00449329\_m1, H60b: Mm04243254\_m1, and Scn4b: Mm01175562\_m1.
Immunohistochemistry. Deparaffinization washes were as follows: 2 × 3 min xylenes, 3 min xylenes:ethanol (1:1),
3 min 95% ethanol, 3 min 80% ethanol, 3 min 70% ethanol, 3 min 50% ethanol, H2O rinse. Heat-mediated antigen
retrieval: 20 min at 95 °C in citrate buffer (pH 6) or Tris-EDTA buffer (pH 9). Sections were blocked in 20% goat
serum in PBS for 1 hour, followed by overnight incubation in primary antibody at 4 °C; GFAP-stained slides were
blocked with a mouse-on-mouse kit (Vector). Following wash, secondary antibody incubation was 1 hour at room
temperature. Slides were mounted and sealed with DAPI fluormount-G (Southern Biotech). AIF1 slides were
prepared from free-floating 40-μm coronal sections. Primary antibodies: mouse anti-aggregated HTT (1:750;
DSHB; MW8), mouse anti-SQSTM1/p62 (1:300; Abcam; AB56416), rabbit anti-NeuN (1:750; Millipore; ABN78),
mouse anti-DARPP32 (1:250; SCBT; H-3; sc-271111), rabbit anti-AIF1 (1:500; Wako), mouse anti-GFAP (1:500;
Millipore; MAB3402). Secondary antibodies: Alexa 488 anti-mouse (1:1000; Life Technologies), Alexa 568
anti-rabbit (1:1000; Life Technologies).
Image acquisition and analysis. For all immunolabeled sections, 12-bit images were acquired with an IX-81
laser-scanning confocal microscope with Fluoview 1000 software (Olympus) using a 60x/1.42 NA oil objective,
with the exception of AIF/GFAP which used a 40x/1.30 NA oil objective. For each secondary antibody, acquisition parameters were set such that a brain section with no primary antibody emitted no fluorescent signal and
settings were maintained for the entire set of sections. Z-stack numbers and thickness were kept consistent for
each set of sections. Maximum z-projections were compiled using ImageJ54. NeuN and/or DAPI masks were
automatically created using ImageJ default thresholds, and used to measure neuronal and/or nuclear expression
of MW8, p62, and DARPP32 (Fig. 5B). AIF1 and GFAP were manually counted. Synaptophysin was quantified as
percent area of image with synaptophysin immunoreactivity. Experimenters were blind to genotype for antibody
application, image acquisition, and analysis.

Behavior.

Elevated Plus Maze. The plus maze was made of white acrylic with two open arms (25x5 × 0.5;
room lux ~475) and two closed arms (25x5 × 16 cm) extending from a central platform elevated 50 cm above
the floor. Each session began by placing a mouse in the intersection of the arms with its head directed toward
the closed arm located opposite of the experimenter and ended after 10 minutes of free exploration. Activity was
video recorded and analyzed using EthoVision XT 8 (Noldus).
Light/Dark Exploration. The light/dark exploration box used in this experiment was constructed of acrylic plastic divided into a clear, brightly illuminated side (27 × 27 × 30 cm; room lux ~475) and a black, fully enclosed side
(18 × 37 × 30 cm) separated by a 5.5 × 5.5 cm opening that permitted the animals to move freely between each
compartment. Each trial began by placing a mouse in the illuminated section of the apparatus facing the entrance
to the dark section, and ended after 10 minutes of free exploration. Activity was video recorded and analyzed
using EthoVision XT 8 (Noldus).
Porsolt Swim Test. Mice were placed into a clear 8-quart bucket (28 cm tall, 22 cm in diameter) filled ¾ full with
room temperature water. Each mouse was placed into the bucket for a single 6-minute session, and swimming
activity was recorded using a camera mounted on a tripod oriented toward the side of the apparatus. Inactivity
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during the last 4 minutes of each session was assessed by two separate experimenters blind to genotype (interrater
reliability = 0.89), and a single composite score was calculated for subsequent analyses.
Sucrose Consumption Test. Mice were given a sucrose eating challenge to determine whether free access to
sucrose would produce different levels of consumption between the genotypes. For these sessions the mice were
given 95% sucrose pellets (AIN-76A, TestDiet, Richmond, IN) for 10 hours per day for 4 days, and normal lab
chow for 14 hours. The amount of sucrose and chow consumed was measured daily by weight of 5 mg sucrose
pellets/chow consumed and expressed as g/kg of bodyweight.
Sucrose Preference Test. Two-bottle sucrose preference testing occurred in the WWU vivarium over eight days.
On day 1, animals were single housed and provided access to two identical 50 mL dual bearing sipper tubes
containing tap water. On day 2, one of the tap water tubes was replaced with a 2% sucrose solution, and mice
were provided free access to both sipper tubes for 72 hours. On day 5, the sipper tube containing the 2% sucrose
solution was replaced with a 4% sucrose solution, and mice were provided free access for another 72 hours. The
location of the sipper tube containing sucrose solution relative to tap water was counterbalanced between experimental animals and rotated each day to avoid place preference. Every 24 hours, experimenters weighed both
sipper tubes to determine consumption from each. The amount consumed from each tube was expressed as a
percentage total consumption per day; average consumption for each sipper tube during each 72-hour period
was compared between genotypes
Operant Testing. Operant testing was conducted in 16 aluminium/steel 9-hole box (14 cm × 13.5 cm × 13.5 cm)
operant chambers (Campden Instruments, UK). On the rear wall of each chamber situated 15 mm from the grid
floor, a horizontal 9-hole light array was fixed that had 9 response holes (11 mm diameter and 2 mm apart) that
contained lights at the rear and infra-red (IR) sensors at the front, such that nose poke responses to light stimuli
could be detected with an IR beam break. For the present experiments only the central response hole (hole 5 of 9)
was used with the other holes blocked. On the inner of the front wall a food magazine was placed that allowed the
mouse to recover sweet liquid rewards (Yazoo strawberry milk, Campina Ltd, UK), delivered by peristaltic pump
after a successful response to the light stimuli. Initial training consisted of non-contingent reward presentations
to the magazine that were signalled by the illumination of a light in the magazine. Removal of the head from the
magazine was detected by an IR beam across the magazine entrance which then reset the trail. This was followed
by training the mice to respond with a nose poke to illuminated hole 5 on the light array. A response in lit hole 5
extinguished the light and illuminated the magazine light to signal reward delivery. On removal of the head from
the magazine, the magazine light was extinguished and after a 2 s intertrial interval, a new trial began with the
illumination of the stimulus light in hole 5 thereby continuing the fixed ratio 1 (FR1) schedule of reinforcement.
Once all mice could successfully complete 30 trials in a 30 minute session, the reward seeking probes began. Nine
45 minute FR1 sessions were run using, 3 (x3) counterbalanced reward pump durations (40 ms, 60 ms, 100 ms),
to determine sensitivity to different reward magnitudes with the key outcome measure being number of rewards
obtained.

Statistical Analysis. Statistics were processed in R 3.2.355. Data were tested for normality (Anderson-Darling
test)56 and homoscedasticity (Levene’s test)57. If data met parametric assumptions, we fit linear models analysed
by ANOVA. If data violated these parametric assumptions, Kruskal-Wallis test was used as an omnibus test and
followed up with Dunn’s test to determine whether pairwise differences between genotypes were significant with
Bonferroni corrections for multiple post-hoc comparisons. Data presented in Figs 2–6 used boxplots - horizontal
lines indicate 25th, 50th and 75th percentile, while the vertical whiskers indicate the range of data. Data falling
outside 1.5 times the interquartile range are graphed as isolated points, but were not excluded from statistical
analysis58. Simulated distributions for power analysis were constructed with the mvrnorm function in the MASS
package59,60. The elastic net classifier was constructed using glmnet59. Endpoint QRT-PCR and IHC data and code
for power analysis are available at https://github.com/seth-ament/hd_endpoints. Graphics were produced using
ggplot261 and Illustrator (Adobe).
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